Cytosorbents Cor (CTSO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -2,701 | 469 | -1,478 | -20,719 | -13,152 |
| Depreciation Amortization | 1,817 | 1,226 | 595 | 2,125 | 1,509 |
| Accounts receivable | 560 | 257 | -80 | -1,720 | -629 |
| Other Working Capital | 135 | 869 | -388 | -4,378 | -3,135 |
| Other Operating Activity | -7,363 | -7,796 | -2,114 | 10,265 | 3,320 |
| Operating Cash Flow | $-7,552 | $-4,975 | $-3,465 | $-14,428 | $-12,087 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -56 | -39 | -2 | -284 | -215 |
| Purchase Sale Intangibles | -68 | -140 | -45 | -385 | -330 |
| Other Investing Activity | -68 | -140 | -45 | -385 | -330 |
| Investing Cash Flow | $-124 | $-179 | $-47 | $-669 | $-545 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 0 | 0 | N/A | 15,000 | 15,000 |
| Debt Repayment | 0 | 0 | 0 | -5,000 | -5,000 |
| Common Stock Issued | 1,439 | 6,831 | 6,832 | N/A | N/A |
| Other Financing Activity | 5,392 | 0 | 0 | -669 | -836 |
| Financing Cash Flow | $6,831 | $6,831 | $6,832 | $9,331 | $9,164 |
| Exchange Rate Effect | 139 | 285 | 26 | -85 | 21 |
| Beginning Cash Position | 9,764 | 9,764 | 9,764 | 15,615 | 15,615 |
| End Cash Position | 9,058 | 11,726 | 13,110 | 9,764 | 12,168 |
| Net Cash Flow | $-706 | $1,962 | $3,346 | $-5,851 | $-3,447 |
| Free Cash Flow | |||||
| Operating Cash Flow | -7,552 | -4,975 | -3,465 | -14,428 | -12,087 |
| Capital Expenditure | -56 | -39 | -2 | -284 | -215 |
| Free Cash Flow | -7,608 | -5,014 | -3,467 | -14,712 | -12,302 |